Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations

The latest US drug development news and highlights from our Performance Tracker.

The US FDA ran hot and cold for sponsors this week. Here's your news in brief. Mylan NV is the latest to sponsor of a Neulasta (pegfilgrastim) biosimilar to strikeout at FDA, becoming the fourth company to receive a complete response letter (CRL) for a copycat candidate.

AcelRx Pharmaceuticals Inc. also ran into an agency stop sign with a CRL for its acute pain opioid Dsuvia...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet